Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sullivan Ayuso

Surgery Evanston, IL Medical Doctor

NPI 1194220921 CMS profile 4734446

2650 Ridge Ave., Walgreen 2507, Evanston, IL 60201

Open in the dashboard

General payments

$74,813

65 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sullivan Ayuso of Evanston, IL is reported in the CMS Open Payments database as having received $74,813 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,075 33
2024 General $25,765 8
2023 General $2,223 15
2022 General $1,481 7
2021 General $133 1
2019 General $136 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sullivan Ayuso
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Sullivan Ayuso were reported at $45,075. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Sullivan Ayuso Surgery median Middle half National median
2019 $136 $253 $82–$1,521 $163
2020 $0 $131 $40–$706 $114
2021 $133 $168 $50–$904 $132
2022 $1,481 $224 $76–$1,218 $149
2023 $2,223 $253 $82–$1,255 $160
2024 $25,765 $279 $90–$1,381 $164
2025 $45,075 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $68,407 23 payments
  2. W. L. Gore & Associates, Inc. $1,857 13 payments
  3. Intuitive Surgical, Inc. $1,357 6 payments
  4. Davol Inc. $1,109 9 payments
  5. Enterra Medical, Inc. $1,010 4 payments
  6. Medtronic, Inc. $675 7 payments
  7. Innovation Technologies Inc $212 1 payment
  8. Allergan Inc. $133 1 payment
  9. CONMED Corporation $52 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $50,000 2 payments
  2. Consulting Fee $11,000 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,500 4 payments
  4. Food and Beverage $4,246 41 payments
  5. Travel and Lodging $3,067 15 payments
  6. Education $1,000 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies $25,000 1 payment
  2. OverStitch Endoscopic Suturing System $11,000 2 payments
  3. ORBERA Intragastric Balloon System $5,849 5 payments
  4. GORE BIO-A Tissue Reinforcement $1,525 9 payments
  5. General - EndoChoice $1,203 8 payments
  6. DAVINCI XI $1,000 1 payment
  7. Phasix Mesh $973 8 payments
  8. Signia $400 5 payments
  9. Da Vinci Surgical System $357 5 payments
  10. GORE ENFORM Preperitoneal Biomaterial $319 3 payments
  11. Other $1,178 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

94

Median for General Surgery: 59

Drug cost

$1,132

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enoxaparin Sodium Generic 11 $947
Ondansetron Hcl Generic 27 $78
Tramadol Hcl Generic 36 $55
Oxycodone Hcl Generic 20 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record